"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2017/0282104 A1,043-911-689-139-886,2017-10-05,2017,US 201515510539 A,2015-11-09,US 201515510539 A;;US 201462077663 P;;US 2015/0059655 W,2014-11-10,FLUID FILTER WITH OPTICAL KEY AND MANIFOLD WITH OPTICAL LOCK,"Keyed fluid-handling devices comprise a fluid-handling device such as a filter, a bypass, or an adapter and an optical key. The optical keys are amenable to all types of filter component and can be readily retrofitted to existing designs. The optical keys may be formed from a variety of materials and combination of phases. That is, optical keys may comprise one or more solid materials, or perhaps may result from a combination of: solid materials, such as in transparent or semi-transparent polymers or glass; liquid fluids, such as water; and gaseous gaps such as an air gap. Optical keys may be light conduits or light guides. Filter manifolds comprise optical locks to ensure compatibility of the filter components.",3M INNOVATIVE PROPERTIES CO,BAUM SCOTT A;;SCHMOLL JEREMY A;;GRIFFIN MICHAEL E;;ENDER DAVID A;;ASTLE ROBERT E;;MAZZONI JUSTIN M,3M INNOVATIVE PROPERTIES COMPANY (2017-08-08),https://lens.org/043-911-689-139-886,Patent Application,yes,3,3,2,2,0,B01D35/30;;B01D2201/291;;B01D2201/4015;;B01D2201/4061;;B01D2201/4053;;B01D2201/302;;C02F2201/006;;C02F2307/12;;C02F1/001;;C02F2201/004;;B01D2201/291;;B01D2201/4015;;B01D2201/4061;;B01D2201/4053;;B01D35/30;;B01D2201/302;;C02F2201/006;;C02F2307/12;;B01D35/14;;B01D35/147;;B01D35/305;;B01D37/04;;C02F1/001;;C02F2201/004,B01D35/30;;B01D35/14;;B01D35/147;;B01D37/04;;C02F1/00,,0,0,,,,DISCONTINUED
2,WO,A1,WO 2016/077186 A1,175-104-249-555-208,2016-05-19,2016,US 2015/0059655 W,2015-11-09,US 201462077663 P,2014-11-10,FLUID FILTER WITH OPTICAL KEY AND MANIFOLD WITH OPTICAL LOCK,"Keyed fluid-handling devices comprise a fluid-handling device such as a filter, a bypass, or an adapter and an optical key. The optical keys are amenable to all types of filter component and can be readily retrofitted to existing designs. The optical keys may be formed from a variety of materials and combination of phases. That is, optical keys may comprise one or more solid materials, or perhaps may result from a combination of: solid materials, such as in transparent or semi-transparent polymers or glass; liquid fluids, such as water; and gaseous gaps such as an air gap. Optical keys may be light conduits or light guides. Filter manifolds comprise optical locks to ensure compatibility of the filter components.",3M INNOVATIVE PROPERTIES CO,BAUM SCOTT A;;SCHMOLL JEREMY A;;GRIFFIN MICHAEL E;;ENDER DAVID A;;ASTLE ROBERT E;;MAZZONI JUSTIN M,,https://lens.org/175-104-249-555-208,Patent Application,yes,4,3,2,2,0,B01D35/30;;B01D2201/291;;B01D2201/4015;;B01D2201/4061;;B01D2201/4053;;B01D2201/302;;C02F2201/006;;C02F2307/12;;C02F1/001;;C02F2201/004;;B01D2201/291;;B01D2201/4015;;B01D2201/4061;;B01D2201/4053;;B01D35/30;;B01D2201/302;;C02F2201/006;;C02F2307/12;;B01D35/14;;B01D35/147;;B01D35/305;;B01D37/04;;C02F1/001;;C02F2201/004,B01D35/30;;B01D35/00,,0,0,,,,PENDING
3,WO,A1,WO 2024/006781 A1,174-521-853-617-461,2024-01-04,2024,US 2023/0069200 W,2023-06-27,US 202263355861 P;;US 202263398067 P;;US 202263405388 P;;US 202263435063 P,2022-06-27,ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF,The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such as endometriosis and cancer. The compounds are bifunctional molecules comprising a cereblon-binding moiety LBM linked to a ligand ERBM that binds ERα and comprises a benzofused partially saturated 6-membered carbocyclic or heterocyclic ring. [I-3'] wherein ERBM is delected from,RELAY THERAPEUTICS INC,TAYLOR ALEXANDER M;;ARMBRUST KURT;;LEPRE CHRISTOPHER A;;MCLEAN THOMAS H;;FLEMING PAUL R;;MA RULIN;;BAUM ERICH W;;FRIDRICH CARY GRIFFIN;;HE JING;;HEAP CHARLES R;;LARROW JAY F;;NTAGANDA RUKUNDO,,https://lens.org/174-521-853-617-461,Patent Application,yes,84,0,1,1,0,C07D401/14;;A61P35/00;;C07D405/14;;C07D211/88;;C07D471/04;;C07D493/10;;C07D495/10;;C07D498/20;;C07D498/10;;C07D487/04;;C07D471/10;;C07D493/08;;C07D487/10;;C07D487/08;;C07D451/02;;C07D401/04;;C07F5/025,C07D401/14;;A61K31/496;;A61P35/00;;C07D211/88;;C07D401/04;;C07D405/14;;C07D451/02;;C07D471/04;;C07D471/10;;C07D487/04;;C07D487/08;;C07D487/10;;C07D493/08;;C07D493/10;;C07D495/10;;C07D498/10;;C07D498/20;;C07F5/02,,13,9,033-549-709-318-573;;082-442-745-857-387;;053-994-321-857-379;;053-994-321-857-379;;032-351-351-782-346;;007-364-858-655-289;;018-148-915-769-649;;112-355-486-428-406;;032-020-530-493-252,10.1371/journal.pone.0001487;;pmc2198940;;18213395;;10.1146/annurev.biochem.78.101807.093809;;19489725;;pmc3940038;;10.1042/bj20140006;;24576094;;pmc3940038;;10.1042/bj20140006;;24576094;;20609404;;10.1016/j.chembiol.2010.05.011;;pmc2925121;;10.1002/jps.2600660104;;833720;;10.1016/0378-5173(86)90055-4;;26756721;;10.1002/anie.201507978;;28437394;;10.1038/nchembio.2363,"LI ET AL., PLOS ONE, vol. 3, 2008, pages 1487;;BEMDSEN ET AL.: ""Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling"", NAT. STRUCT. MOL. BIOL., vol. 21, 2014, pages 301 - 307;;DESHAIES ET AL., ANN. REV. BIOCHEM., vol. 78, 2009, pages 399 - 434;;SPRATT ET AL.: ""RING domain E3 ubiquitin ligases"", BIOCHEM., vol. 458, 2014, pages 421 - 437;;WANG ET AL.: ""RBR E3 ubiquitin ligases: new structures, new insights, new questions"", NAT. REV. CANCER., vol. 14, 2014, pages 233 - 347;;CREWS C, CHEMISTRY & BIOLOGY, vol. 17, no. 6, 2010, pages 551 - 555;;SCHNNEKLOTH JS JR., CHEMBIOCHEM, vol. 6, no. 1, 2005, pages 40 - 46;;THOMAS SORRELL: ""Handbook of Chemistry and Physics"", 1999, UNIVERSITY SCIENCE BOOKS, article ""Organic Chemistry"";;""March's Advanced Organic Chemistry"", 2001, JOHN WILEY & SONS;;BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1;;GOULD. P.L., INT. J. PHARMACEUTICS, vol. 33, 1986, pages 201 - 217;;M. TOUREC. M. CREWS, ANGEW. CHEM. INT. ED., vol. 55, 2016, pages 1966;;T. UEHARA ET AL., NATURE CHEMICAL BIOLOGY, vol. 13, 2017, pages 675",PENDING
4,WO,A2,WO 2023/220131 A2,094-521-878-662-648,2023-11-16,2023,US 2023/0021668 W,2023-05-10,US 202263364459 P,2022-05-10,PI3Kα INHIBITORS AND METHODS OF USE THEREOF,"The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Kα enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling with the compounds and compositions of the disclosure.",RELAY THERAPEUTICS INC,PAN YUE;;BOEZIO ALESSANDRO;;FRIDRICH CARY GRIFFIN;;KRUEGER ELAINE B;;MOUSTAKAS DEMETRI T;;RAYNOR KEVIN DAVID;;SHORTSLEEVES KELLEY C;;MCLEAN THOMAS H;;DENINNO MICHAEL PAUL;;THOMSON CHRISTOPHER;;LARIVEE ALEXANDRE;;BURNIE ANDREW J;;ATIENZA BREN-JORDAN;;PERREAULT CHRISTIAN;;MAERTENS GAETAN;;MOHAMED TAREK;;LEPITRE THOMAS;;BAUM ERICH W,,https://lens.org/094-521-878-662-648,Patent Application,yes,0,0,2,2,0,A61P35/00;;C07D403/04;;C07D403/14;;C07D235/02;;C07D471/04;;C07D235/30;;C07D237/24;;C07D231/38;;C07D215/38;;C07D237/08;;C07D233/64;;C07D205/04;;C07D211/58;;C07D237/20;;C07D209/96;;C07D239/70;;C07D239/28;;C07D271/10;;C07D209/54;;C07D263/52;;C07D405/12;;C07D213/75;;C07D207/27;;C07D413/04;;C07D417/04;;C07D295/26;;C07D239/48;;C07D307/14;;C07D243/08;;C07D401/04;;C07D277/38;;C07D209/08;;C07D417/12;;C07D413/06;;C07D409/12;;C07D277/82;;C07D487/04;;C07D401/06;;C07D333/72;;C07D307/84;;C07D335/02;;C07C211/29;;C07C2601/08;;C07C2602/42;;C07C255/46;;C07C2601/02;;C07C2602/18;;C07C237/24;;C07C235/40;;C07C233/13;;C07C215/68,C07C233/80;;A61K31/167,,0,0,,,,PENDING
5,WO,A3,WO 2023/220131 A3,140-309-082-685-818,2024-01-04,2024,US 2023/0021668 W,2023-05-10,US 202263364459 P,2022-05-10,PI3Kα INHIBITORS AND METHODS OF USE THEREOF,"The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Kα enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling with the compounds and compositions of the disclosure.",RELAY THERAPEUTICS INC,PAN YUE;;BOEZIO ALESSANDRO;;FRIDRICH CARY GRIFFIN;;KRUEGER ELAINE B;;MOUSTAKAS DEMETRI T;;RAYNOR KEVIN DAVID;;SHORTSLEEVES KELLEY C;;MCLEAN THOMAS H;;DENINNO MICHAEL PAUL;;THOMSON CHRISTOPHER;;LARIVEE ALEXANDRE;;BURNIE ANDREW J;;ATIENZA BREN-JORDAN;;PERREAULT CHRISTIAN;;MAERTENS GAETAN;;MOHAMED TAREK;;LEPITRE THOMAS;;BAUM ERICH W;;GUNAYDIN HAKAN,,https://lens.org/140-309-082-685-818,Search Report,yes,4,0,2,2,0,A61P35/00;;C07D403/04;;C07D403/14;;C07D235/02;;C07D471/04;;C07D235/30;;C07D237/24;;C07D231/38;;C07D215/38;;C07D237/08;;C07D233/64;;C07D205/04;;C07D211/58;;C07D237/20;;C07D209/96;;C07D239/70;;C07D239/28;;C07D271/10;;C07D209/54;;C07D263/52;;C07D405/12;;C07D213/75;;C07D207/27;;C07D413/04;;C07D417/04;;C07D295/26;;C07D239/48;;C07D307/14;;C07D243/08;;C07D401/04;;C07D277/38;;C07D209/08;;C07D417/12;;C07D413/06;;C07D409/12;;C07D277/82;;C07D487/04;;C07D401/06;;C07D333/72;;C07D307/84;;C07D335/02;;C07C211/29;;C07C2601/08;;C07C2602/42;;C07C255/46;;C07C2601/02;;C07C2602/18;;C07C237/24;;C07C235/40;;C07C233/13;;C07C215/68,C07C25/02;;A61K31/03;;A61P35/00,,1,0,,,"DATABASE PUBCHEM SUBSTANCE ANONYMOUS : ""101-81-5"", XP093126735, retrieved from PUBCHEM",PENDING
